Machine signal
Active cluster sell — 4 distinct insiders, $7.2M, window ends Jul 22, 2026.
Figures computed from official regulatory filings — .
Analysttarget 48.4 USD (+65%) · consensus 5/5 · 6 buy · 0 hold · 0 sell
Ownershipinsiders 3.14% · institutions 112.39% · short 33.6% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Surrozen, Inc./DE only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of patients with idiopathic pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
76 buys25 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| TCG Crossover GP II, LLC | Sell | $3.5M | SEC |
| TCG Crossover GP II, LLC | Sell | $3.5M | SEC |
| Maleki Andrew Pedrum | Award | $11.5K | SEC |
| Li Yang | Award | $13.5K | Unusual size | SEC |
| Parker Craig Ctrack record | Award | $13.2K | Unusual size | SEC |
| Williams Charles Otrack record | Award | $13.5K | Unusual size | SEC |
| Kutzkey Timtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| BJERKHOLT ERICtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| WOODHOUSE DAVID J | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| CHAI CHRISTOPHER Y | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Rothenberg Mace | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Berkenblit Anna | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Haak-Frendscho Mary | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Li Yang | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Li Yang | Sell | $52.8K | SEC |
| Parker Craig Ctrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Williams Charles Otrack record | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Williams Charles Otrack record | Sell | $67.9K | SEC |
| Li Yang | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Parker Craig Ctrack record | Sell | $150.8K | SEC |
| Parker Craig Ctrack record | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Williams Charles Otrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Li Yang | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| TCG Crossover Fund II, L.P.track record | Buy | $189.5K | conv 31Cluster | SEC |
| TCG Crossover Fund II, L.P.track record | Buy | $189.5K | conv 31Cluster | SEC |